Kexing Biopharm Expands Global Presence at CPHI Milan 2026

Kexing Biopharm recently showcased its innovative drug pipeline at CPHI Milan 2026, highlighting its biosimilars and products available in the global market. The company engaged with diverse stakeholders, including drug purchasers and biotech firms, emphasizing its expanding international footprint.

Kexing has built a robust overseas commercialization platform, securing agreements on over 30 products across therapeutic areas such as oncology and metabolic diseases. Its marketing network spans approximately 70 countries and it has filed nearly 200 overseas registration applications.

In Europe, Kexing's core product, albumin-bound paclitaxel, is marketed in multiple regions. The company is planning to establish subsidiaries in several European countries to enhance market presence and cater to regional needs effectively.

Strategically focused on "Innovation+ internationalization," Kexing is developing high-value biosimilars while its drug pipeline in cancer and chronic diseases attracts significant interest. With a mature manufacturing system, Kexing stands as a significant player in the global biopharmaceutical industry.